BDR Pharma Launches Oral Solution for Prostate Cancer in India

BDENZA ORAL SOLUTION is a first-of-its-kind oral solution that addresses the challenges faced by many prostate cancer patients, offering convenience, reduced side effects, and affordability. Reportedly, this solution will soon hit the Indian markets at a price of INR 27,000 for 150 ml.

Mumbai-based BDR Pharmaceuticals has launched an oral solution (32mg/ml) designed for the management of prostate cancer to offer relief to millions of patients worldwide.

BDENZA ORAL SOLUTION is a first-of-its-kind oral solution that addresses the challenges faced by many prostate cancer patients, offering convenience, reduced side effects, and affordability. Reportedly, this solution will soon hit the Indian markets at a price of INR 27,000 for 150 ml.

Sharing his views, Dr Aravind Badiger, director, technical formulation, BDR Pharmaceuticals, said, “Changing how we treat prostate cancer, BDENZA ORAL SOLUTION brings a mix of benefits to make things better for patients. BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help to improve the patient compliance to a great extent.’’

Prostate cancer has become a growing concern globally, with approximately 1.2 million new cases diagnosed each year and an estimated 375,000 associated deaths, as reported by the World Health Organisation (WHO).

Notably, in the 1990s, it held the position of the 8th most common cancer in males; however, by 2015, it had risen to the 3rd most prevalent cancer in India. In 2016 alone, India reported a total of 37,416 cases of prostate cancer, and projections indicate an anticipated increase to over 47,000 cases by the year 2025.

Given that a significant portion of the population affected by prostate cancer comprises the elderly, challenges such as administering high-dosage medications have emerged as noteworthy considerations.

Based in Mumbai, BDR Pharmaceuticals was founded in 2002 by Dharmesh Shah. The company focuses on therapeutic segments such as oncology and critical care, with a growing presence in dermatology and gynaecology. They have two API and formulation facilities at Gujarat, and Uttarakhand, and a pellet facility at Hyderabad.

Going forward, BDR Pharmaceuticals aims to become a strategic innovator and enhance healthcare by providing society with innovative products and medicines at affordable prices in the life-saving category,

Earlier on November 23, Redcliffe lab launched a prostate health index test to address rising prostate cancer cases in India. The PHI test is a straightforward and cost-effective blood test that aids in the identification of patients who genuinely require a prostate biopsy. It is particularly beneficial for men aged 50 and above with non-suspicious digital rectal examination (DRE) results and a total prostate-specific antigen (PSA) range of 4 to 10 mg/ml.